 | • レポートコード：MRC2012A1680 • 出版社/出版日：GlobalInfoResearch / 2020年12月21日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、133ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品、医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、がん用抗体薬物複合体の世界市場を広く調査・分析し、今後の市場展望をまとめております。がん用抗体薬物複合体の種類別市場規模（第1世代＆第2世代ADC、第3世代ADC）、用途別市場規模（病院、診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Novartis、Biogen Idec、AbbVie、Merck、Stem CentRx、Roche、Millennium、Bristol-Myers Squibb、UCB、Nordic Nanovector、Viventia Biotechnologies、Biotest AG、AbGenomics Corporation、Seattle Genetics、PDL BioPharma、Helix BioPharma、Progenics Pharmaceuticals、 ・地域別グローバル市場分析 2015年-2020年 ・がん用抗体薬物複合体の北米市場（アメリカ、カナダ、メキシコ） ・がん用抗体薬物複合体のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・がん用抗体薬物複合体のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・がん用抗体薬物複合体の南米市場（ブラジル、アルゼンチン） ・がん用抗体薬物複合体の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：第1世代＆第2世代ADC、第3世代ADC ・用途別分析：病院、診療所、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Cancer Antibody Drug Conjugates market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Cancer Antibody Drug Conjugates market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Cancer Antibody Drug Conjugates market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Cancer Antibody Drug Conjugates market has been segmented into
First & Second Generation ADCs
Third Generation ADCs
By Application, Cancer Antibody Drug Conjugates has been segmented into:
Hospitals
Clinics
Other
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Cancer Antibody Drug Conjugates market presented in the report. This section sheds light on the sales growth of different regional and country-level Cancer Antibody Drug Conjugates markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Cancer Antibody Drug Conjugates market.
The report offers in-depth assessment of the growth and other aspects of the Cancer Antibody Drug Conjugates market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Cancer Antibody Drug Conjugates Market Share Analysis
Cancer Antibody Drug Conjugates competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Cancer Antibody Drug Conjugates sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Cancer Antibody Drug Conjugates sales, revenue and market share for each player covered in this report.
The major players covered in Cancer Antibody Drug Conjugates are:
Novartis
Biogen Idec
AbbVie
Merck
Stem CentRx
Roche
Millennium
Bristol-Myers Squibb
UCB
Nordic Nanovector
Viventia Biotechnologies
Biotest AG
AbGenomics Corporation
Seattle Genetics
PDL BioPharma
Helix BioPharma
Progenics Pharmaceuticals
Among other players domestic and global, Cancer Antibody Drug Conjugates market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Cancer Antibody Drug Conjugates product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Cancer Antibody Drug Conjugates, with price, sales, revenue and global market share of Cancer Antibody Drug Conjugates in 2018 and 2019.
Chapter 3, the Cancer Antibody Drug Conjugates competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Cancer Antibody Drug Conjugates breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Cancer Antibody Drug Conjugates market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Cancer Antibody Drug Conjugates sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Cancer Antibody Drug Conjugates Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Cancer Antibody Drug Conjugates Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 First & Second Generation ADCs
1.2.3 Third Generation ADCs
1.3 Market Analysis by Application
1.3.1 Overview: Global Cancer Antibody Drug Conjugates Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Overview of Global Cancer Antibody Drug Conjugates Market
1.4.1 Global Cancer Antibody Drug Conjugates Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Novartis SWOT Analysis
2.1.4 Novartis Product and Services
2.1.5 Novartis Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Biogen Idec
2.2.1 Biogen Idec Details
2.2.2 Biogen Idec Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Biogen Idec SWOT Analysis
2.2.4 Biogen Idec Product and Services
2.2.5 Biogen Idec Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 AbbVie
2.3.1 AbbVie Details
2.3.2 AbbVie Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 AbbVie SWOT Analysis
2.3.4 AbbVie Product and Services
2.3.5 AbbVie Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Merck SWOT Analysis
2.4.4 Merck Product and Services
2.4.5 Merck Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Stem CentRx
2.5.1 Stem CentRx Details
2.5.2 Stem CentRx Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Stem CentRx SWOT Analysis
2.5.4 Stem CentRx Product and Services
2.5.5 Stem CentRx Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Roche
2.6.1 Roche Details
2.6.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Roche SWOT Analysis
2.6.4 Roche Product and Services
2.6.5 Roche Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Millennium
2.7.1 Millennium Details
2.7.2 Millennium Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Millennium SWOT Analysis
2.7.4 Millennium Product and Services
2.7.5 Millennium Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Bristol-Myers Squibb
2.8.1 Bristol-Myers Squibb Details
2.8.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Bristol-Myers Squibb SWOT Analysis
2.8.4 Bristol-Myers Squibb Product and Services
2.8.5 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 UCB
2.9.1 UCB Details
2.9.2 UCB Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 UCB SWOT Analysis
2.9.4 UCB Product and Services
2.9.5 UCB Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Nordic Nanovector
2.10.1 Nordic Nanovector Details
2.10.2 Nordic Nanovector Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Nordic Nanovector SWOT Analysis
2.10.4 Nordic Nanovector Product and Services
2.10.5 Nordic Nanovector Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 Viventia Biotechnologies
2.11.1 Viventia Biotechnologies Details
2.11.2 Viventia Biotechnologies Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Viventia Biotechnologies SWOT Analysis
2.11.4 Viventia Biotechnologies Product and Services
2.11.5 Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.12 Biotest AG
2.12.1 Biotest AG Details
2.12.2 Biotest AG Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Biotest AG SWOT Analysis
2.12.4 Biotest AG Product and Services
2.12.5 Biotest AG Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.13 AbGenomics Corporation
2.13.1 AbGenomics Corporation Details
2.13.2 AbGenomics Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 AbGenomics Corporation SWOT Analysis
2.13.4 AbGenomics Corporation Product and Services
2.13.5 AbGenomics Corporation Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.14 Seattle Genetics
2.14.1 Seattle Genetics Details
2.14.2 Seattle Genetics Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Seattle Genetics SWOT Analysis
2.14.4 Seattle Genetics Product and Services
2.14.5 Seattle Genetics Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.15 PDL BioPharma
2.15.1 PDL BioPharma Details
2.15.2 PDL BioPharma Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 PDL BioPharma SWOT Analysis
2.15.4 PDL BioPharma Product and Services
2.15.5 PDL BioPharma Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.16 Helix BioPharma
2.16.1 Helix BioPharma Details
2.16.2 Helix BioPharma Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Helix BioPharma SWOT Analysis
2.16.4 Helix BioPharma Product and Services
2.16.5 Helix BioPharma Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.17 Progenics Pharmaceuticals
2.17.1 Progenics Pharmaceuticals Details
2.17.2 Progenics Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Progenics Pharmaceuticals SWOT Analysis
2.17.4 Progenics Pharmaceuticals Product and Services
2.17.5 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Cancer Antibody Drug Conjugates Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Cancer Antibody Drug Conjugates Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Cancer Antibody Drug Conjugates Manufacturer Market Share in 2019
3.3.2 Top 6 Cancer Antibody Drug Conjugates Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Cancer Antibody Drug Conjugates Sales, Revenue and Market Share by Regions
4.1.1 Global Cancer Antibody Drug Conjugates Sales and Market Share by Regions (2015-2020)
4.1.2 Global Cancer Antibody Drug Conjugates Revenue and Market Share by Regions (2015-2020)
4.2 North America Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
4.3 Europe Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
4.5 South America Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Cancer Antibody Drug Conjugates Sales, Revenue and Market Share by Country
5.1.1 North America Cancer Antibody Drug Conjugates Sales and Market Share by Country (2015-2020)
5.1.2 North America Cancer Antibody Drug Conjugates Revenue and Market Share by Country (2015-2020)
5.2 United States Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
5.3 Canada Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
5.4 Mexico Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Cancer Antibody Drug Conjugates Sales, Revenue and Market Share by Country
6.1.1 Europe Cancer Antibody Drug Conjugates Sales and Market Share by Country (2015-2020)
6.1.2 Europe Cancer Antibody Drug Conjugates Revenue and Market Share by Country (2015-2020)
6.2 Germany Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
6.3 UK Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
6.4 France Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
6.5 Russia Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
6.6 Italy Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Cancer Antibody Drug Conjugates Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Cancer Antibody Drug Conjugates Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Cancer Antibody Drug Conjugates Revenue and Market Share by Regions (2015-2020)
7.2 China Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
7.3 Japan Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
7.4 Korea Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
7.5 India Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
7.7 Australia Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Cancer Antibody Drug Conjugates Sales, Revenue and Market Share by Country
8.1.1 South America Cancer Antibody Drug Conjugates Sales and Market Share by Country (2015-2020)
8.1.2 South America Cancer Antibody Drug Conjugates Revenue and Market Share by Country (2015-2020)
8.2 Brazil Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
8.3 Argentina Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Cancer Antibody Drug Conjugates Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Cancer Antibody Drug Conjugates Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Cancer Antibody Drug Conjugates Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
9.3 Turkey Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
9.4 Egypt Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
9.5 South Africa Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Cancer Antibody Drug Conjugates Sales and Market Share by Type (2015-2020)
10.2 Global Cancer Antibody Drug Conjugates Revenue and Market Share by Type (2015-2020)
10.3 Global Cancer Antibody Drug Conjugates Price by Type (2015-2020)
11 Global Cancer Antibody Drug Conjugates Market Segment by Application
11.1 Global Cancer Antibody Drug Conjugates Sales Market Share by Application (2015-2020)
11.2 Global Cancer Antibody Drug Conjugates Revenue Market Share by Application (2015-2020)
11.3 Global Cancer Antibody Drug Conjugates Price by Application (2015-2020)
12 Market Forecast
12.1 Global Cancer Antibody Drug Conjugates Sales, Revenue and Growth Rate (2021-2025)
12.2 Cancer Antibody Drug Conjugates Market Forecast by Regions (2021-2025)
12.2.1 North America Cancer Antibody Drug Conjugates Market Forecast (2021-2025)
12.2.2 Europe Cancer Antibody Drug Conjugates Market Forecast (2021-2025)
12.2.3 Asia-Pacific Cancer Antibody Drug Conjugates Market Forecast (2021-2025)
12.2.4 South America Cancer Antibody Drug Conjugates Market Forecast (2021-2025)
12.2.5 Middle East & Africa Cancer Antibody Drug Conjugates Market Forecast (2021-2025)
12.3 Cancer Antibody Drug Conjugates Market Forecast by Type (2021-2025)
12.3.1 Global Cancer Antibody Drug Conjugates Sales Forecast by Type (2021-2025)
12.3.2 Global Cancer Antibody Drug Conjugates Market Share Forecast by Type (2021-2025)
12.4 Cancer Antibody Drug Conjugates Market Forecast by Application (2021-2025)
12.4.1 Global Cancer Antibody Drug Conjugates Sales Forecast by Application (2021-2025)
12.4.2 Global Cancer Antibody Drug Conjugates Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Cancer Antibody Drug Conjugates Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Cancer Antibody Drug Conjugates by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Cancer Antibody Drug Conjugates Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Novartis Basic Information, Manufacturing Base and Competitors
Table 8. Novartis Cancer Antibody Drug Conjugates Major Business
Table 9. Novartis Cancer Antibody Drug Conjugates Total Revenue (USD Million) (2017-2018)
Table 10. Novartis SWOT Analysis
Table 11. Novartis Cancer Antibody Drug Conjugates Product and Services
Table 12. Novartis Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Biogen Idec Basic Information, Manufacturing Base and Competitors
Table 14. Biogen Idec Cancer Antibody Drug Conjugates Major Business
Table 15. Biogen Idec Cancer Antibody Drug Conjugates Total Revenue (USD Million) (2017-2018)
Table 16. Biogen Idec SWOT Analysis
Table 17. Biogen Idec Cancer Antibody Drug Conjugates Product and Services
Table 18. Biogen Idec Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. AbbVie Basic Information, Manufacturing Base and Competitors
Table 20. AbbVie Cancer Antibody Drug Conjugates Major Business
Table 21. AbbVie Cancer Antibody Drug Conjugates Total Revenue (USD Million) (2017-2018)
Table 22. AbbVie SWOT Analysis
Table 23. AbbVie Cancer Antibody Drug Conjugates Product and Services
Table 24. AbbVie Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Merck Basic Information, Manufacturing Base and Competitors
Table 26. Merck Cancer Antibody Drug Conjugates Major Business
Table 27. Merck Cancer Antibody Drug Conjugates Total Revenue (USD Million) (2017-2018)
Table 28. Merck SWOT Analysis
Table 29. Merck Cancer Antibody Drug Conjugates Product and Services
Table 30. Merck Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Stem CentRx Basic Information, Manufacturing Base and Competitors
Table 32. Stem CentRx Cancer Antibody Drug Conjugates Major Business
Table 33. Stem CentRx Cancer Antibody Drug Conjugates Total Revenue (USD Million) (2017-2018)
Table 34. Stem CentRx SWOT Analysis
Table 35. Stem CentRx Cancer Antibody Drug Conjugates Product and Services
Table 36. Stem CentRx Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Roche Basic Information, Manufacturing Base and Competitors
Table 38. Roche Cancer Antibody Drug Conjugates Major Business
Table 39. Roche Cancer Antibody Drug Conjugates Total Revenue (USD Million) (2017-2018)
Table 40. Roche SWOT Analysis
Table 41. Roche Cancer Antibody Drug Conjugates Product and Services
Table 42. Roche Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Millennium Basic Information, Manufacturing Base and Competitors
Table 44. Millennium Cancer Antibody Drug Conjugates Major Business
Table 45. Millennium Cancer Antibody Drug Conjugates Total Revenue (USD Million) (2017-2018)
Table 46. Millennium SWOT Analysis
Table 47. Millennium Cancer Antibody Drug Conjugates Product and Services
Table 48. Millennium Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 50. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Major Business
Table 51. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Total Revenue (USD Million) (2017-2018)
Table 52. Bristol-Myers Squibb SWOT Analysis
Table 53. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Product and Services
Table 54. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. UCB Basic Information, Manufacturing Base and Competitors
Table 56. UCB Cancer Antibody Drug Conjugates Major Business
Table 57. UCB Cancer Antibody Drug Conjugates Total Revenue (USD Million) (2017-2018)
Table 58. UCB SWOT Analysis
Table 59. UCB Cancer Antibody Drug Conjugates Product and Services
Table 60. UCB Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. Nordic Nanovector Basic Information, Manufacturing Base and Competitors
Table 62. Nordic Nanovector Cancer Antibody Drug Conjugates Major Business
Table 63. Nordic Nanovector Cancer Antibody Drug Conjugates Total Revenue (USD Million) (2017-2018)
Table 64. Nordic Nanovector SWOT Analysis
Table 65. Nordic Nanovector Cancer Antibody Drug Conjugates Product and Services
Table 66. Nordic Nanovector Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. Viventia Biotechnologies Basic Information, Manufacturing Base and Competitors
Table 68. Viventia Biotechnologies Cancer Antibody Drug Conjugates Major Business
Table 69. Viventia Biotechnologies Cancer Antibody Drug Conjugates Total Revenue (USD Million) (2017-2018)
Table 70. Viventia Biotechnologies SWOT Analysis
Table 71. Viventia Biotechnologies Cancer Antibody Drug Conjugates Product and Services
Table 72. Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 73. Biotest AG Basic Information, Manufacturing Base and Competitors
Table 74. Biotest AG Cancer Antibody Drug Conjugates Major Business
Table 75. Biotest AG Cancer Antibody Drug Conjugates Total Revenue (USD Million) (2017-2018)
Table 76. Biotest AG SWOT Analysis
Table 77. Biotest AG Cancer Antibody Drug Conjugates Product and Services
Table 78. Biotest AG Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 79. AbGenomics Corporation Basic Information, Manufacturing Base and Competitors
Table 80. AbGenomics Corporation Cancer Antibody Drug Conjugates Major Business
Table 81. AbGenomics Corporation Cancer Antibody Drug Conjugates Total Revenue (USD Million) (2017-2018)
Table 82. AbGenomics Corporation SWOT Analysis
Table 83. AbGenomics Corporation Cancer Antibody Drug Conjugates Product and Services
Table 84. AbGenomics Corporation Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 85. Seattle Genetics Basic Information, Manufacturing Base and Competitors
Table 86. Seattle Genetics Cancer Antibody Drug Conjugates Major Business
Table 87. Seattle Genetics Cancer Antibody Drug Conjugates Total Revenue (USD Million) (2017-2018)
Table 88. Seattle Genetics SWOT Analysis
Table 89. Seattle Genetics Cancer Antibody Drug Conjugates Product and Services
Table 90. Seattle Genetics Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 91. PDL BioPharma Basic Information, Manufacturing Base and Competitors
Table 92. PDL BioPharma Cancer Antibody Drug Conjugates Major Business
Table 93. PDL BioPharma Cancer Antibody Drug Conjugates Total Revenue (USD Million) (2017-2018)
Table 94. PDL BioPharma SWOT Analysis
Table 95. PDL BioPharma Cancer Antibody Drug Conjugates Product and Services
Table 96. PDL BioPharma Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 97. Helix BioPharma Basic Information, Manufacturing Base and Competitors
Table 98. Helix BioPharma Cancer Antibody Drug Conjugates Major Business
Table 99. Helix BioPharma Cancer Antibody Drug Conjugates Total Revenue (USD Million) (2017-2018)
Table 100. Helix BioPharma SWOT Analysis
Table 101. Helix BioPharma Cancer Antibody Drug Conjugates Product and Services
Table 102. Helix BioPharma Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 103. Progenics Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 104. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Major Business
Table 105. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Total Revenue (USD Million) (2017-2018)
Table 106. Progenics Pharmaceuticals SWOT Analysis
Table 107. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Product and Services
Table 108. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 109. Global Cancer Antibody Drug Conjugates Sales by Manufacturer (2018-2019) (K Pcs)
Table 110. Global Cancer Antibody Drug Conjugates Revenue by Manufacturer (2018-2019) (USD Million)
Table 111. Global Cancer Antibody Drug Conjugates Sales by Regions (2015-2020) (K Pcs)
Table 112. Global Cancer Antibody Drug Conjugates Sales Market Share by Regions (2015-2020)
Table 113. Global Cancer Antibody Drug Conjugates Revenue by Regions (2015-2020) (USD Million)
Table 114. North America Cancer Antibody Drug Conjugates Sales by Countries (2015-2020) (K Pcs)
Table 115. North America Cancer Antibody Drug Conjugates Sales Market Share by Countries (2015-2020)
Table 116. North America Cancer Antibody Drug Conjugates Revenue by Countries (2015-2020) (USD Million)
Table 117. North America Cancer Antibody Drug Conjugates Revenue Market Share by Countries (2015-2020)
Table 118. Europe Cancer Antibody Drug Conjugates Sales by Countries (2015-2020) (K Pcs)
Table 119. Europe Cancer Antibody Drug Conjugates Sales Market Share by Countries (2015-2020)
Table 120. Europe Cancer Antibody Drug Conjugates Revenue by Countries (2015-2020) (USD Million)
Table 121. Asia-Pacific Cancer Antibody Drug Conjugates Sales by Regions (2015-2020) (K Pcs)
Table 122. Asia-Pacific Cancer Antibody Drug Conjugates Sales Market Share by Regions (2015-2020)
Table 123. Asia-Pacific Cancer Antibody Drug Conjugates Revenue by Regions (2015-2020) (USD Million)
Table 124. South America Cancer Antibody Drug Conjugates Sales by Countries (2015-2020) (K Pcs)
Table 125. South America Cancer Antibody Drug Conjugates Sales Market Share by Countries (2015-2020)
Table 126. South America Cancer Antibody Drug Conjugates Revenue by Countries (2015-2020) (USD Million)
Table 127. South America Cancer Antibody Drug Conjugates Revenue Market Share by Countries (2015-2020)
Table 128. Middle East & Africa Cancer Antibody Drug Conjugates Sales by Countries (2015-2020) (K Pcs)
Table 129. Middle East & Africa Cancer Antibody Drug Conjugates Sales Market Share by Countries (2015-2020)
Table 130. Middle East & Africa Cancer Antibody Drug Conjugates Revenue by Countries (2015-2020) (USD Million)
Table 131. Middle East & Africa Cancer Antibody Drug Conjugates Revenue Market Share by Countries (2015-2020)
Table 132. Global Cancer Antibody Drug Conjugates Sales by Type (2015-2020) (K Pcs)
Table 133. Global Cancer Antibody Drug Conjugates Sales Share by Type (2015-2020)
Table 134. Global Cancer Antibody Drug Conjugates Revenue by Type (2015-2020) (USD Million)
Table 135. Global Cancer Antibody Drug Conjugates Revenue Share by Type (2015-2020)
Table 136. Global Cancer Antibody Drug Conjugates Sales by Application (2015-2020) (K Pcs)
Table 137. Global Cancer Antibody Drug Conjugates Sales Share by Application (2015-2020)
Table 138. Global Cancer Antibody Drug Conjugates Sales Forecast by Regions (2021-2025) (K Pcs)
Table 139. Global Cancer Antibody Drug Conjugates Market Share Forecast by Regions (2021-2025)
Table 140. Global Cancer Antibody Drug Conjugates Sales Forecast by Type (2021-2025) (K Pcs)
Table 141. Global Cancer Antibody Drug Conjugates Market Share Forecast by Type (2021-2025)
Table 142. Global Cancer Antibody Drug Conjugates Sales Forecast by Application (2021-2025)
Table 143. Global Cancer Antibody Drug Conjugates Market Share Forecast by Application (2021-2025)
Table 144. Direct Channel Pros & Cons
Table 145. Indirect Channel Pros & Cons
Table 146. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Cancer Antibody Drug Conjugates Picture
Figure 2. Global Sales Market Share of Cancer Antibody Drug Conjugates by Type in 2019
Figure 3. First & Second Generation ADCs Picture
Figure 4. Third Generation ADCs Picture
Figure 5. Cancer Antibody Drug Conjugates Sales Market Share by Application in 2018
Figure 6. Hospitals Picture
Figure 7. Clinics Picture
Figure 8. Other Picture
Figure 9. Global Cancer Antibody Drug Conjugates Market Status and Outlook (2015-2025) (USD Million)
Figure 10. United States Cancer Antibody Drug Conjugates Revenue (Value) and Growth Rate (2015-2025)
Figure 11. Canada Cancer Antibody Drug Conjugates Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Mexico Cancer Antibody Drug Conjugates Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Germany Cancer Antibody Drug Conjugates Revenue (Value) and Growth Rate (2015-2025)
Figure 14. France Cancer Antibody Drug Conjugates Revenue (Value) and Growth Rate (2015-2025)
Figure 15. UK Cancer Antibody Drug Conjugates Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Russia Cancer Antibody Drug Conjugates Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Italy Cancer Antibody Drug Conjugates Revenue (Value) and Growth Rate (2015-2025)
Figure 18. China Cancer Antibody Drug Conjugates Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Japan Cancer Antibody Drug Conjugates Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Korea Cancer Antibody Drug Conjugates Revenue (Value) and Growth Rate (2015-2025)
Figure 21. India Cancer Antibody Drug Conjugates Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Southeast Asia Cancer Antibody Drug Conjugates Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Australia Cancer Antibody Drug Conjugates Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 24. Brazil Cancer Antibody Drug Conjugates Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Egypt Cancer Antibody Drug Conjugates Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Saudi Arabia Cancer Antibody Drug Conjugates Revenue (Value) and Growth Rate (2015-2025)
Figure 27. South Africa Cancer Antibody Drug Conjugates Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Turkey Cancer Antibody Drug Conjugates Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Global Cancer Antibody Drug Conjugates Sales Market Share by Manufacturer in 2019
Figure 30. Global Cancer Antibody Drug Conjugates Revenue Market Share by Manufacturer in 2019
Figure 31. Top 3 Cancer Antibody Drug Conjugates Manufacturer (Revenue) Market Share in 2019
Figure 32. Top 6 Cancer Antibody Drug Conjugates Manufacturer (Revenue) Market Share in 2019
Figure 33. Key Manufacturer Market Share Trend
Figure 34. Global Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020) (K Pcs)
Figure 35. Global Cancer Antibody Drug Conjugates Revenue and Growth Rate (2015-2020) (USD Million)
Figure 36. Global Cancer Antibody Drug Conjugates Revenue Market Share by Regions (2015-2020)
Figure 37. Global Cancer Antibody Drug Conjugates Revenue Market Share by Regions in 2018
Figure 38. North America Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
Figure 39. Europe Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
Figure 40. Asia-Pacific Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
Figure 41. South America Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
Figure 42. Middle East & Africa Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020)
Figure 43. North America Cancer Antibody Drug Conjugates Revenue and Growth Rate (2015-2020) (USD Million)
Figure 44. North America Cancer Antibody Drug Conjugates Sales Market Share by Countries (2015-2020)
Figure 45. North America Cancer Antibody Drug Conjugates Sales Market Share by Countries in 2018
Figure 46. North America Cancer Antibody Drug Conjugates Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 47. North America Cancer Antibody Drug Conjugates Revenue Market Share by Countries in 2018
Figure 48. United States Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020) (K Pcs)
Figure 49. Canada Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020) (K Pcs)
Figure 50. Mexico Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020) (K Pcs)
Figure 51. Europe Cancer Antibody Drug Conjugates Revenue and Growth Rate (2015-2020) (USD Million)
Figure 52. Europe Cancer Antibody Drug Conjugates Revenue Market Share by Countries (2015-2020)
Figure 53. Europe Cancer Antibody Drug Conjugates Revenue Market Share by Countries in 2019
Figure 54. Germany Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020) (K Pcs)
Figure 55. UK Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020) (K Pcs)
Figure 56. France Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020) (K Pcs)
Figure 57. Russia Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020) (K Pcs)
Figure 58. Italy Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020) (K Pcs)
Figure 59. Asia-Pacific Cancer Antibody Drug Conjugates Revenue and Growth Rate (2015-2020) (USD Million)
Figure 60. Asia-Pacific Cancer Antibody Drug Conjugates Sales Market Share by Regions 2019
Figure 61. Asia-Pacific Cancer Antibody Drug Conjugates Revenue Market Share by Regions 2019
Figure 62. China Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020) (K Pcs)
Figure 63. Japan Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020) (K Pcs)
Figure 64. Korea Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020) (K Pcs)
Figure 65. India Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020) (K Pcs)
Figure 66. Southeast Asia Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020) (K Pcs)
Figure 67. South America Cancer Antibody Drug Conjugates Revenue and Growth Rate (2015-2020) (USD Million)
Figure 68. South America Cancer Antibody Drug Conjugates Sales Market Share by Countries in 2019
Figure 69. South America Cancer Antibody Drug Conjugates Revenue Market Share by Countries in 2019
Figure 70. Brazil Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020) (K Pcs)
Figure 71. Argentina Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020) (K Pcs)
Figure 72. Middle East and Africa Cancer Antibody Drug Conjugates Revenue and Growth Rate (2015-2020) (USD Million)
Figure 73. Middle East and Africa Cancer Antibody Drug Conjugates Sales Market Share by Countries in 2019
Figure 74. Middle East and Africa Cancer Antibody Drug Conjugates Revenue Market Share by Countries (2015-2020)
Figure 75. Middle East and Africa Cancer Antibody Drug Conjugates Revenue Market Share by Countries in 2019
Figure 76. Saudi Arabia Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020) (K Pcs)
Figure 77. Egypt Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020) (K Pcs)
Figure 78. Turkey Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020) (K Pcs)
Figure 79. South Africa Cancer Antibody Drug Conjugates Sales and Growth Rate (2015-2020) (K Pcs)
Figure 80. Global Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2025) (K Pcs)
Figure 81. Global Cancer Antibody Drug Conjugates Revenue and Growth Rate (2021-2025) (USD Million)
Figure 82. North America Sales Cancer Antibody Drug Conjugates Market Forecast (2021-2025) (K Pcs)
Figure 83. Europe Sales Cancer Antibody Drug Conjugates Market Forecast (2021-2025) (K Pcs)
Figure 84. Asia-Pacific Sales Cancer Antibody Drug Conjugates Market Forecast (2021-2025) (K Pcs)
Figure 85. South America Sales Cancer Antibody Drug Conjugates Market Forecast (2021-2025) (K Pcs)
Figure 86. Middle East & Africa Sales Cancer Antibody Drug Conjugates Market Forecast (2021-2025) (K Pcs)
Figure 87. Sales Channel: Direct Channel vs Indirect Channel
抗体薬物複合体（ADC）の世界市場（～2026年） Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased…- 次世代抗体療法の世界市場（～2026年） The ADCs segment held the largest market share in the historical period and is projected to hold a market share of over 50% by 2025. The Fc engineered antibodies segmented is projected to witness the fastest growth during the forecast period. Market Analysis and Insights: Global Next Generation Anti…
- 高分子医薬品コンジュゲートの世界市場（～2026年） Market Analysis and Insights: Global Polymer Drug Conjugates Market The global Polymer Drug Conjugates market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Polymer Drug Conjugates Scope and Market Size Polymer Drug Conjugat…
- 抗体薬物複合体の世界市場（～2026年） Market Analysis and Insights: Global Antibody Drug Conjugate Market The global Antibody Drug Conjugate market size is projected to reach US$ 1831.1 million by 2026, from US$ 1696.9 million in 2020, at a CAGR of 7.3%% during 2021-2026. Global Antibody Drug Conjugate Scope and Market Size Antibody Dru…
- 抗体薬物複合体の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Antibody Drug Conjugate market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 7.0% in the forecast period of 2020 to 2025 and will expected to reach USD 2288.6 million by 2025, from USD 1746 million in 2019. The Antibody Drug …